Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing innovative biologic therapies using proprietary protein engineering platforms. Its focus includes oncology and immunotherapy, with pipeline candidates like ozekibart (INBRX-109) targeting cancer cell death pathways and INBRX-106 enhancing T-cell responses. The company aims to address high unmet medical needs through targeted, differentiated biologics for cancer and immune-related diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.